Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial

OBJECTIVE: To evaluate risankizumab, a biological therapy that inhibits interleukin 23, in patients with active psoriatic arthritis (PsA) who have responded inadequately or are intolerant to ≥1 conventional synthetic disease-modifying antirheumatic drug (csDMARD). METHODS: In the randomised, placebo...

Descripción completa

Detalles Bibliográficos
Autores principales: Kristensen, Lars Erik, Keiserman, Mauro, Papp, Kim, McCasland, Leslie, White, Douglas, Lu, Wenjing, Wang, Zailong, Soliman, Ahmed M, Eldred, Ann, Barcomb, Lisa, Behrens, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Psoriatic Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8762015/
https://www.ncbi.nlm.nih.gov/pubmed/34911706
http://dx.doi.org/10.1136/annrheumdis-2021-221019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8762015/
https://www.ncbi.nlm.nih.gov/pubmed/34911706
http://dx.doi.org/10.1136/annrheumdis-2021-221019

Ejemplares similares